should compounded semaglutide be refrigerated ✈️ Traveling with Semaglutide?⁠ ⁠ Keep your medication safe with these quick tips:⁠ ⁠ 💡 Use an insulated bag or cooler for unopened vials.⁠ 💡 Always pack it in your carry-on to 10 Must-Know Semaglutide Refrigeration Tips

Pittayanon et al

Research suggests that using Semaglutide for at least 6 months to a year can result in significant, lasting weight loss

During US GLP-1 shortages a few years ago, pharmacies were also permitted to produce compounded semaglutide and tirzepatide, but the FDA says that exemption ended once supplies recovered in early 2025

GLP-1 signaling may improve mitochondrial biogenesis via PGC-1a/nuclear respiratory factor-1/mitochondrial transcription factor A signaling regulated by adiponectin/ adenosine 5-monophosphate (AMP)-activated protein kinase (AMPK)49 and elevates the expression of NAD-dependent protein deacetylase sirtuin 1 (SIRT1), which increases the expression of Parkin, leading to mitophagy activation.50 Evidence strongly suggests that GLP-1 increases ER-mitochondria communication, resulting in higher mitochondrial activity.51 Upregulating SIRT3 expression and activation of the extracellular signal-regulated kinase-Yes-associated protein (ERK-Yap) signaling pathway, as well as the CREB/adiponectin axis may also be involved in the protection of mitochondria by GLP-1.52,53 The improvement of antioxidant stress through GLP-1 signaling seems to be related to the activation of the GLP-1 R/cAMP/PKA signaling pathway and nuclear factor erythroid 2-related factor 2/heme oxygenase 1 signaling pathway.54,55 The GLP-1 RA and Endoplasmic Reticulum (ER) Stress The ER is the basic organelle for the synthesis of a series of important biological molecules, such as proteins, lipids (such as triglycerides), and carbohydrates

Stressors and Midlife Much of the medical literature on heart palpitations and hormones confirms that women in midlife and those entering menopause do experience palpitations

Treatment of nonocclusive lower extremity arterial disease with endovascular stent placement (either covered or noncovered) in the infrainguinal arteries will be reported with arterial vascular stent codes 37236 and 37237 rather than the lower extremity revascularization family of codes 3722437235